This site is intended for US Healthcare Professionals.

Anemia in myelodysplastic syndromes (MDS)

Anemia in myelodysplastic syndromes (MDS)

Anemia is a prevalent obstacle in myelodysplastic syndromes (MDS)2

Sign icon saying 20,000 new cases of MDS are reported each year
Silhouette of people representing the 85% of patients with MDS with anemia

MDS-associated anemia shortens patients’ lives and negatively impacts their quality of life4

Drip bag icon with "94%" in the center

94%

(n=515)

of patients with MDS receive red blood cell (RBC) transfusions for anemia5*

< 5 years

Median overall survival in lower-risk MDS6†

65%

of patients would undergo a different treatment to stop or reduce their transfusion burden, even if it temporarily made them feel worse7‡

Chronic anemia and transfusion dependence are the main clinical challenges in lower-risk MDS2

*Per SEER registry data for patients with MDS from 2001 to 2007.5

†Analysis of 2396 patients from a prospective, noninterventional, longitudinal registry from January 2008 to December 2018, followed up to December 2019.6

‡Based on results of an online survey completed by 361 patients with MDS, 234 (65%) of whom had received a blood transfusion.7

Are your patients’ treatment goals being met?

While existing treatments can be effective for some patients, many remain dependent on transfusions, which can make them vulnerable to poorer overall survival.1,8-10

Additional treatment options are needed to address anemia in MDS2

References:

1. Lewis R, Bewersdorf JP, Zeidan AM. Clinical management of anemia in patients with myelodysplastic syndromes: an update on emerging therapeutic options. Cancer Manag Res. 2021;13:645-657. 2. Kubasch AS, Platzbecker U. Setting fire to ESA and EMA resistance: new targeted treatment options in lower risk myelodysplastic syndromes. Int J Mol Sci. 2019;20(16):3853. doi:10.3390/ijms20163853 3. Lymphoma & Leukemia Society. Myelodysplastic syndrome (MDS) research funded by LLS. Accessed April 27, 2023. https://www.lls.org/research/myelodysplastic-syndrome-mds-research-funded-lls 4. Kaka S, Jahangirnia A, Beauregard N, Davis A, Tinmouth A, Chin-Yee N. Red blood cell transfusion in myelodysplastic syndromes: a systematic review. Transfus Med. 2022;32(1):3-23. 5. Ramsey SD, McCune JS, Blough DK, et al. Patterns of blood product use among patients with myelodysplastic syndrome. Vox Sang. 2012;102(4):331-337. 6. Madry K, Lis K, Fenaux P, et al. Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): a report from the European MDS registry. Br J Haematol. 2023;200(4):451-461. 7. Sekeres MA, Maciejewski JP, List AF, et al. Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based survey. Oncologist. 2011;16(6):901-911. 8. Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood. 2012;120(12):2454-2465. 9. Harnan S, Ren S, Gomersall T, et al. Association between transfusion status and overall survival in patients with myelodysplastic syndromes: a systemic literature review and meta-analysis. Acta Haematol. 2016;136(1):23-42. 10. Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica. 2006;91(12):1588-1590.